Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

BACKGROUND: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or clinical malaria; however the underlying mechanisms that...

Descripción completa

Detalles Bibliográficos
Autores principales: Guinovart, Caterina, Aponte, John J., Sacarlal, Jahit, Aide, Pedro, Leach, Amanda, Bassat, Quique, Macete, Eusébio, Dobaño, Carlota, Lievens, Marc, Loucq, Christian, Ballou, W. Ripley, Cohen, Joe, Alonso, Pedro L.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666156/
https://www.ncbi.nlm.nih.gov/pubmed/19365567
http://dx.doi.org/10.1371/journal.pone.0005165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666156/
https://www.ncbi.nlm.nih.gov/pubmed/19365567
http://dx.doi.org/10.1371/journal.pone.0005165

Ejemplares similares